Compare VABK & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VABK | LXEO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.1M | 348.7M |
| IPO Year | 2013 | 2023 |
| Metric | VABK | LXEO |
|---|---|---|
| Price | $53.75 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $25.11 |
| AVG Volume (30 Days) | 15.1K | ★ 2.5M |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | 12.70 | ★ 39.81 |
| EPS | ★ 3.82 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.35 | $2.55 |
| 52 Week High | $55.00 | $10.99 |
| Indicator | VABK | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 48.31 |
| Support Level | $46.61 | $2.72 |
| Resistance Level | $55.00 | $3.56 |
| Average True Range (ATR) | 1.15 | 0.40 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 61.75 | 19.69 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.